These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1547 related items for PubMed ID: 31584231

  • 1. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Anker SD, Zannad F, EMPEROR-Reduced Trial Committees and Investigators.
    Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
    Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M, EMPEROR-Preserved Trial Committees and Investigators.
    Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
    [Abstract] [Full Text] [Related]

  • 3. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M.
    Lancet; 2020 Sep 19; 396(10254):819-829. PubMed ID: 32877652
    [Abstract] [Full Text] [Related]

  • 4. Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure.
    Packer M, Butler J, Filippatos G, Zannad F, Ferreira JP, Zeller C, Brueckmann M, Jamal W, Pocock SJ, Anker SD, EMPEROR Trial Committees and Investigators.
    Eur J Heart Fail; 2020 Dec 19; 22(12):2393-2398. PubMed ID: 33251659
    [Abstract] [Full Text] [Related]

  • 5. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T, Ferrannini G, Mellbin L, Benson L, Cosentino F, McMurray JJV, Dahlström U, Lund LH, Savarese G.
    J Card Fail; 2022 Jul 19; 28(7):1050-1062. PubMed ID: 35550428
    [Abstract] [Full Text] [Related]

  • 6. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, Dreisbach JG, Labinjoh C, Lang NN, Lennie V, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Speirits IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JJV, Jhund PS, Petrie MC, Sattar N.
    Circulation; 2021 Feb 09; 143(6):516-525. PubMed ID: 33186500
    [Abstract] [Full Text] [Related]

  • 7. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
    Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Seronde MF, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, EMPEROR-Preserved Trial Committees and Investigators.
    Eur J Heart Fail; 2020 Dec 09; 22(12):2383-2392. PubMed ID: 33251670
    [Abstract] [Full Text] [Related]

  • 8. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
    Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi EA, Ponikowski P, Perrone SV, Januzzi JL, Verma S, Böhm M, Ferreira JP, Pocock SJ, Zannad F, Packer M.
    Circulation; 2021 Jan 26; 143(4):337-349. PubMed ID: 33175585
    [Abstract] [Full Text] [Related]

  • 9. Can we go beyond surrogates?
    Drexler A.
    J Diabetes; 2017 Nov 26; 9(11):976-977. PubMed ID: 28692750
    [Abstract] [Full Text] [Related]

  • 10. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
    Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Faber J, Malik ME, Fosbøl EL, Bruun NE, Forman JL, Jensen LT, Møller JE, Schou M.
    Lancet Diabetes Endocrinol; 2021 Feb 26; 9(2):106-116. PubMed ID: 33357505
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
    McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, DAPA-HF Committees and Investigators.
    Eur J Heart Fail; 2019 May 26; 21(5):665-675. PubMed ID: 30895697
    [Abstract] [Full Text] [Related]

  • 13. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F, EMPEROR-Reduced Trial Committees and Investigators.
    J Am Coll Cardiol; 2021 Mar 23; 77(11):1381-1392. PubMed ID: 33736819
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
    Hamid AK, Tayem AA, Al-Aish ST, Al Sakini AS, Hadi DD, Al-Aish RT.
    Ther Adv Cardiovasc Dis; 2024 Mar 23; 18():17539447241289067. PubMed ID: 39400108
    [Abstract] [Full Text] [Related]

  • 16. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
    Rau M, Thiele K, Hartmann NK, Schuh A, Altiok E, Möllmann J, Keszei AP, Böhm M, Marx N, Lehrke M.
    Cardiovasc Diabetol; 2021 Jan 07; 20(1):6. PubMed ID: 33413355
    [Abstract] [Full Text] [Related]

  • 17. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
    Jensen J, Omar M, Kistorp C, Poulsen MK, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Fosbøl E, Bruun NE, Videbæk L, Frederiksen PH, Møller JE, Schou M.
    Trials; 2019 Jun 21; 20(1):374. PubMed ID: 31227014
    [Abstract] [Full Text] [Related]

  • 18. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M, Anker SD, Butler J, Filippatos G, Zannad F.
    JAMA Cardiol; 2017 Sep 01; 2(9):1025-1029. PubMed ID: 28768320
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.